We believe that the pharmaceuticals giant Merck (NYSE: MRK) is currently a better pick over its peer, AbbVie stock. MRK stock trades at 14x forward earnings, versus 20x for ABBV. We think this gap in ...

Keytruda, Merck's flagship oncology drug, drives significant revenue growth, with a solid market position and patent protection ensuring continued growth. Merck is the second largest player in the ...

Pfizer's Eliquis, a blood thinner and one of its best-selling therapies, will lose patent exclusivity within the next few ...

Merck shares began peeling back in early 2024, mostly on concerns about looming patent expirations for its breadwinning drug. The trading crowd changed its collective mind a couple months ago, sending ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically positioning itself for further growth by diversifying and expanding its ...

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...

Merck has increased its dividend for 14 consecutive years. Its 10-year dividend growth rate of 5.4% is only decent. Merck increased its revenue from $39.5 billion in FY 2015 to $64.2 billion in FY ...

Merck aims to cut $3B in costs by end of 2027 Job reductions planned across admin, sales and R&D Company to shrink global real estate and manufacturing Savings to support biotech, R&D and Keytruda ...

Trial adjourned, new jury due to reconvene in September Kennedy helped organize litigation against Merck before HHS role Merck denies claims, cites scientific evidence supporting Gardasil safety Feb ...

Merck’s search for its next blockbuster product continues to go beyond cancer. The pharmaceutical giant has agreed to pay $10.8 billion to acquire Prometheus Biosciences, a biotech with a Phase ...